Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSV-hIFNβ-NIS in Relapsed/Refractory Hematologic Malignancies
NCT03017820Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2017
- Primary completion
- Dec 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter in multiple myeloma (MM), acute myeloid leukemia (AML), lymphoma and 1 more (7 arms), sponsored by Mayo Clinic. Primary endpoint: Incidence of adverse events of grade 3 or higher up to 2 years. Started Apr 2017; status: recruiting.
02
Drugs
recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter
03
Conditions
multiple myeloma (MM)acute myeloid leukemia (AML)lymphomahistiocytic and dendritic cell neoplasms
Beyond the preview
Go deeper on NCT03017820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017820.